The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.
 
Chrisann Kyi
Honoraria - OncLive/MJH Life Sciences; Total Health
Consulting or Advisory Role - Scenic Biotech
Research Funding - Acrivon Therapeutics; Bristol Myers Squibb,; Centessa Pharmaceuticals; Eisai; Gritstone Bio; Incyte; Merus
Travel, Accommodations, Expenses - Gritstone Bio
 
Marloes Van Dongen
No Relationships to Disclose
 
Sylvie Rottey
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); ipsen (Inst); Janssen (Inst); MSD (Inst); Pfizer (Inst)
Speakers' Bureau - BMS GmbH & Co. KG (Inst); BMS GmbH & Co. KG (Inst); ipsen (Inst); Roche (Inst)
Research Funding - BMS GmbH & Co. KG (Inst)
Travel, Accommodations, Expenses - Merck (Inst); MSD (Inst)
 
Ignacio Melero Bermejo
Honoraria - PharmaMar
Consulting or Advisory Role - Alligator Bioscience; Amunix; AstraZeneca/MedImmune; BiolineRx; Boston Pharmaceuticals; Bright Peak Therapeutics; Bristol-Myers Squibb; Catalym; Curon Biopharmaceutical; Dompé farmaceutici; EMD Serono; F-star; Genmab; Genmab; GlaxoSmithKline; Gossamer Bio; Hookipa Pharma; ImmuneSensor Therapeutics; Merus; Moderna Therapeutics; Monopteros Therapeutics; MSD; Noxxon Pharma; Numab; Pieris Pharmaceuticals; Roche/Genentech; Sanofi; SERVIER; Shattuck Labs
Research Funding - Alligator Bioscience; AstraZeneca; Bioncotech; Bristol-Myers Squibb; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche/Genentech
 
Diana Mittag
Employment - Merus
 
Dane Gouveia
Employment - Merus
 
Kees Bol
Employment - Merus
 
Chris Yan
Employment - Merus
 
Andrew K. Joe
Employment - Merus
Leadership - Merus
Stock and Other Ownership Interests - Merus; Sanofi
 
Gianluca Laus
Employment - Merus
Stock and Other Ownership Interests - AstraZeneca; Merus
 
Victor Moreno
Employment - START
Consulting or Advisory Role - Abbvie; Affimed Therapeutics; AstraZeneca; Basilea; Bayer; BMS; Janssen Oncology; Merck; Roche
Speakers' Bureau - Bayer; Pierre Fabre
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ADC Therapeutics (Inst); Amgen (Inst); Ascendis Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); Biomea Fusion (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Crescendo Bioscience (Inst); Cullinan Oncology (Inst); E-therapeutics (Inst); Eisai (Inst); F-Star Biotechnology (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); hemavant (Inst); HiFiBiO Therapeutics (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Menarini (Inst); Merck (Inst); MonTa Biosciences (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Revolution Medicines (Inst); RigonTEC (Inst); Roche (Inst); Sanofi (Inst); Sierra Oncology (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Transgene (Inst)
Expert Testimony - Medscape/Bayer; Nanobiotix
Travel, Accommodations, Expenses - Sanofi/Regeneron
Other Relationship - BMS